Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Small molecule immuno-oncology therapeutic agents.

Toogood PL.

Bioorg Med Chem Lett. 2018 Feb 1;28(3):319-329. doi: 10.1016/j.bmcl.2017.12.044. Epub 2017 Dec 20. Review.

PMID:
29326017
2.

Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity.

Hu X, Liu X, Moisan J, Wang Y, Lesch CA, Spooner C, Morgan RW, Zawidzka EM, Mertz D, Bousley D, Majchrzak K, Kryczek I, Taylor C, Van Huis C, Skalitzky D, Hurd A, Aicher TD, Toogood PL, Glick GD, Paulos CM, Zou W, Carter LL.

Oncoimmunology. 2016 Nov 4;5(12):e1254854. doi: 10.1080/2162402X.2016.1254854. eCollection 2016.

3.

Corrigendum: Sterol metabolism controls TH17 differentiation by generating endogenous RORγ agonists.

Hu X, Wang Y, Hao LY, Liu X, Lesch CA, Sanchez BM, Wendling JM, Morgan RW, Aicher TD, Carter LL, Toogood PL, Glick GD.

Nat Chem Biol. 2015 Sep;11(9):741. doi: 10.1038/nchembio0915-741b. No abstract available.

PMID:
26284677
4.

Sterol metabolism controls T(H)17 differentiation by generating endogenous RORγ agonists.

Hu X, Wang Y, Hao LY, Liu X, Lesch CA, Sanchez BM, Wendling JM, Morgan RW, Aicher TD, Carter LL, Toogood PL, Glick GD.

Nat Chem Biol. 2015 Feb;11(2):141-7. doi: 10.1038/nchembio.1714. Epub 2015 Jan 5. Erratum in: Nat Chem Biol. 2015 Sep;11(9):741.

PMID:
25558972
5.

Synthesis of (-)-PNU-286607 by asymmetric cyclization of alkylidene barbiturates.

Ruble JC, Hurd AR, Johnson TA, Sherry DA, Barbachyn MR, Toogood PL, Bundy GL, Graber DR, Kamilar GM.

J Am Chem Soc. 2009 Mar 25;131(11):3991-7. doi: 10.1021/ja808014h.

PMID:
19260642
6.

Discovery and SAR of benzyl phenyl ethers as inhibitors of bacterial phenylalanyl-tRNA synthetase.

Montgomery JI, Toogood PL, Hutchings KM, Liu J, Narasimhan L, Braden T, Dermyer MR, Kulynych AD, Smith YD, Warmus JS, Taylor C.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):665-9. doi: 10.1016/j.bmcl.2008.12.054. Epub 2008 Dec 24.

PMID:
19121937
7.

The synthesis of azadirachtin: a potent insect antifeedant.

Ley SV, Abad-Somovilla A, Anderson JC, Ayats C, Bänteli R, Beckmann E, Boyer A, Brasca MG, Brice A, Broughton HB, Burke BJ, Cleator E, Craig D, Denholm AA, Denton RM, Durand-Reville T, Gobbi LB, Göbel M, Gray BL, Grossmann RB, Gutteridge CE, Hahn N, Harding SL, Jennens DC, Jennens L, Lovell PJ, Lovell HJ, de la Puente ML, Kolb HC, Koot WJ, Maslen SL, McCusker CF, Mattes A, Pape AR, Pinto A, Santafianos D, Scott JS, Smith SC, Somers AQ, Spilling CD, Stelzer F, Toogood PL, Turner RM, Veitch GE, Wood A, Zumbrunn C.

Chemistry. 2008;14(34):10683-704. doi: 10.1002/chem.200801103.

PMID:
18821532
8.

A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.

Menu E, Garcia J, Huang X, Di Liberto M, Toogood PL, Chen I, Vanderkerken K, Chen-Kiang S.

Cancer Res. 2008 Jul 15;68(14):5519-23. doi: 10.1158/0008-5472.CAN-07-6404.

9.

Mitochondrial drugs.

Toogood PL.

Curr Opin Chem Biol. 2008 Aug;12(4):457-63. doi: 10.1016/j.cbpa.2008.06.002. Epub 2008 Jul 2. Review.

PMID:
18602018
10.

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.

Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R, Niesvizky R, Cho H, Ely S, Moore MA, Chen-Kiang S.

Cancer Res. 2006 Aug 1;66(15):7661-7.

11.

The kinome is not enough.

Toogood PL.

Chem Biol. 2005 Oct;12(10):1057-8. Review.

12.

2-Aminoquinazoline inhibitors of cyclin-dependent kinases.

Bathini Y, Singh I, Harvey PJ, Keller PR, Singh R, Micetich RG, Fry DW, Dobrusin EM, Toogood PL.

Bioorg Med Chem Lett. 2005 Sep 1;15(17):3881-5.

PMID:
15993068
13.

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.

Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H, Keller PR, McNamara DJ, Sherry D, Zhu T, Brodfuehrer J, Choi C, Barvian MR, Fry DW.

J Med Chem. 2005 Apr 7;48(7):2388-406.

PMID:
15801831
14.

Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.

VanderWel SN, Harvey PJ, McNamara DJ, Repine JT, Keller PR, Quin J 3rd, Booth RJ, Elliott WL, Dobrusin EM, Fry DW, Toogood PL.

J Med Chem. 2005 Apr 7;48(7):2371-87.

PMID:
15801830
15.

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL.

Mol Cancer Ther. 2004 Nov;3(11):1427-38.

16.

A short and efficient synthesis of L-5,5,5,5',5',5'-hexafluoroleucine from N-Cbz-L-serine.

Anderson JT, Toogood PL, Marsh EN.

Org Lett. 2002 Nov 28;4(24):4281-3.

PMID:
12443078
17.

Progress toward the development of agents to modulate the cell cycle.

Toogood PL.

Curr Opin Chem Biol. 2002 Aug;6(4):472-8. Review.

PMID:
12133723
18.

Inhibition of protein-protein association by small molecules: approaches and progress.

Toogood PL.

J Med Chem. 2002 Apr 11;45(8):1543-58. Review. No abstract available.

PMID:
11931608
19.

Total Synthesis of Motuporin and 5-[L-Ala]-Motuporin.

Samy R, Kim HY, Brady M, Toogood PL.

J Org Chem. 1999 Apr 16;64(8):2711-2728.

PMID:
11674341
20.

Cyclin-dependent kinase inhibitors for treating cancer.

Toogood PL.

Med Res Rev. 2001 Nov;21(6):487-98. Review.

PMID:
11607930
21.

Synthesis and biological evaluation of didemnin photoaffinity analogues.

Vera MD, Pfizenmayer AJ, Ding X, Ahuja D, Toogood PL, Joullié MM.

Bioorg Med Chem Lett. 2001 Jul 23;11(14):1871-4.

PMID:
11459650
22.

Inhibition of protein synthesis by didemnins: cell potency and SAR.

Ahuja D, Geiger A, Ramanjulu JM, Vera MD, SirDeshpande B, Pfizenmayer A, Abazeed M, Krosky DJ, Beidler D, Joullié MM, Toogood PL.

J Med Chem. 2000 Nov 2;43(22):4212-8.

PMID:
11063617
23.

Inhibition of protein synthesis by didemnin B: how EF-1alpha mediates inhibition of translocation.

Ahuja D, Vera MD, SirDeshpande BV, Morimoto H, Williams PG, Joullié MM, Toogood PL.

Biochemistry. 2000 Apr 18;39(15):4339-46.

PMID:
10757982
24.

Inhibition of protein synthesis by didemnin B is not sufficient to induce apoptosis in human mammary carcinoma (MCF7) cells.

Beidler DR, Ahuja D, Wicha MS, Toogood PL.

Biochem Pharmacol. 1999 Sep 15;58(6):1067-74.

PMID:
10509759
25.

Synthesis of an Enantiomerically Pure Serine-Derived Thiazole.

Sowinski JA, Toogood PL.

J Org Chem. 1996 Nov 1;61(22):7671-7676.

PMID:
11667720
26.

Mechanism of protein synthesis inhibition by didemnin B in vitro.

SirDeshpande BV, Toogood PL.

Biochemistry. 1995 Jul 18;34(28):9177-84.

PMID:
7619818
27.

Ligand recognition by influenza virus. The binding of bivalent sialosides.

Glick GD, Toogood PL, Wiley DC, Skehel JJ, Knowles JR.

J Biol Chem. 1991 Dec 15;266(35):23660-9.

28.

Monovalent sialosides that bind tightly to influenza A virus.

Toogood PL, Galliker PK, Glick GD, Knowles JR.

J Med Chem. 1991 Oct;34(10):3138-40. No abstract available.

PMID:
1920363

Supplemental Content

Loading ...
Support Center